Background
Materials and methods
Patients
Clinical data analysis
Statistical analysis
Results
Patient characteristics
Characteristics | Number (%) | |
---|---|---|
Sex | Male | 56 (69) |
Female | 25 (31) | |
Age (years) | ≤ 60 | 67 (83) |
> 60 | 14 (17) | |
Performance status | ECOG 0/1 | 54 (67) |
ECOG ≥ 2 | 25 (31) | |
Missing | 2 (2) | |
Extranodal involvement | < 2 | 29 (36) |
≥ 2 | 52 (64) | |
Serum LDH | Normal | 38 (47) |
Increased | 40 (49) | |
Missing | 3 (4) | |
Ann Arbor stage | I/II | 18 (22)/11 (13) |
III/IV | 7 (9)/45 (56) | |
B symptoms | Absence | 30 (37) |
Presence | 51 (63) | |
Bone marrow invasion | Absent | 68 (84) |
Present | 7 (9) | |
Not evaluated | 6 (7) | |
NK Prognostic Index | Group 1/2 | 3 (4)/12 (15) |
Group 3/4 | 21 (26)/42 (52) | |
Missing | 3 (4) | |
International Prognostic Index | Low/Low-intermediate | 22 (27)/19 (24) |
High-intermediate/High | 26 (32)/11 (13) | |
Missing | 3 (4) | |
Clinical presentation | GI manifestation | 55 (68) |
Non-GI manifestation | 26 (32) | |
Nasal involvement | Absence | 63 (78) |
Presence | 18 (22) |
Pattern of GI tract involvement
Treatment
Treatment outcomes
Characteristics | Surgery + Chemotherapy | Chemotherapy |
P
|
---|---|---|---|
Age (years) | |||
≤ 60 | 25 (76) | 30 (88) | 0.13 |
> 60 | 8 (24) | 4 (12) | |
Performance status | |||
ECOG 0/1 | 27 (84) | 20 (59) | 0.03 |
ECOG ≥ 2 | 5 (16) | 14 (41) | |
Extranodal involvement | |||
< 2 | 15 (45) | 7 (21) | 0.04 |
≤ 2 | 18 (55) | 27 (79) | |
Serum LDH | |||
Normal | 17 (52) | 15 (44) | 0.62 |
Increased | 15 (45) | 19 (56) | |
Missing | 1 (3) | ||
Ann Arbor stage | |||
I/II | 15 (45) | 5 (15) | < 0.01 |
III/IV | 18 (55) | 29 (85) | |
B symptoms | |||
Absence | 15 (45) | 9 (27) | 0.13 |
Presence | 18 (55) | 25 (73) | |
Bone marrow invasion | |||
Absence | 29 (88) | 29 (85) | 0.20 |
Presence | 2 (6) | 5 (15) | |
Not evaluated | 2 (6) | 0 (0) | |
Nasal involvement | |||
Absence | 30 (91) | 19 (56) | < 0.01 |
Presence | 3 (9) | 15 (44) |